HCW Biologics Inc (HCWB)vsModerna Inc (MRNA)
HCWB
HCW Biologics Inc
$1.87
-4.10%
HEALTHCARE · Cap: $4.04M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 33049% more annual revenue ($2.23B vs $6.72M). HCWB leads profitability with a -83.1% profit margin vs -141.4%. HCWB earns a higher WallStSmart Score of 41/100 (D).
HCWB
Hold41
out of 100
Grade: D
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 1970.0% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -28.3% — below average capital efficiency
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Price/Book, Revenue Growth. Revenue growth of 1970.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
HCWB carries more volatility with a beta of 2.38 — expect wider price swings.
HCWB is growing revenue faster at 1970.0% — sustainability is the question.
HCWB generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
HCWB scores higher overall (41/100 vs 21/100) and 1970.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?